Overview

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Status:
Active, not recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating women with non-metastatic breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

NSABP Foundation Inc

Collaborator:

National Cancer Institute (NCI)

Treatments:

Albumin-Bound Paclitaxel
Cyclophosphamide
Docetaxel
Doxorubicin
Estrogens
Liposomal doxorubicin
Paclitaxel
Progesterone